FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours not roomanas:									

_	lance and Address of Deposition Deposit	2 Issuer Name and Ticker or Trading Symbol					
	Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940					
	obligations may continue. See						

1. Name and Address of Reporting Person* SBLENDORIO GLENN			2. Issuer Name and Ticker or Trading Symbol IVERIC bio, Inc. [ISEE]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
SDLENDORIO GLENN				X	Director	10% Owner			
(Last)	(Last) (First) (Middle) C/O IVERIC BIO, INC.		Date of Earliest Transaction (Month/Day/Year)	X	Officer (give title below)	Other (specify below)			
C/O IVERIC BIO			03/30/2022	CEO					
8 SYLVAN WAY	<i>T</i>								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Fili	ng (Check Applicable			
PARSIPPANY	NJ	07054		X	Form filed by One Re	porting Person			
					Form filed by More th	an One Reporting			
(City)	(State)	(Zip)			Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	03/30/2022		M ⁽¹⁾		1,213	A	\$2.94	280,902	D			
Common Stock	03/30/2022		S ⁽¹⁾		1,213	D	\$17.004(2)	279,689	D			
Common Stock	03/31/2022		M ⁽¹⁾		1,400	A	\$2.94	281,089	D			
Common Stock	03/31/2022		S ⁽¹⁾		1,400	D	\$17.02 ⁽³⁾	279,689	D			
Common Stock	04/01/2022		M ⁽¹⁾		40,756	Α	\$2.94	320,445	D			
Common Stock	04/01/2022		S ⁽¹⁾		40,756	D	\$17.5(4)	279,689	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$2.94	03/30/2022		M ⁽¹⁾			1,213	(5)	12/18/2027	Common Stock	1,213	\$0	367,156	D	
Stock Option (right to buy)	\$2.94	03/31/2022		M ⁽¹⁾			1,400	(5)	12/18/2027	Common Stock	1,400	\$0	365,756	D	
Stock Option (right to buy)	\$2.94	04/01/2022		M ⁽¹⁾			40,756	(5)	12/18/2027	Common Stock	40,756	\$0	325,000	D	

- 1. The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022
- 2. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from \$17.00 to \$17.01 per share on March 30, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
- 3. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from \$17.00 to \$17.02 per share on March 31, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
- 4. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from \$17.00 to \$17.83 per share on April 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range
- 5. This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.

Remarks:

/s/ Todd Anderman, as Attorney-in-Fact for Glenn P.

04/01/2022

<u>Sblendorio</u>

** Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.